New Brunswick, NJNCT07703436Now EnrollingIRB Ready

Grade 2 IDH1-mutant Glioma Clinical Trial in New Brunswick, NJ

Access cutting-edge grade 2 idh1-mutant glioma treatment through this phase 2 clinical trial at a research site in New Brunswick. Study-provided care at no cost to qualified participants.

Sponsored by Nuvation Bio Inc.

Quick Self-Assessment

See if you qualify for this New Brunswick location

Preparing your pre-screening questions…

Expert Care in New Brunswick

Access grade 2 idh1-mutant glioma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related grade 2 idh1-mutant glioma treatment provided free

Apply for This New Brunswick Location

Check if you qualify for this grade 2 idh1-mutant glioma clinical trial in New Brunswick, NJ

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to New Brunswick

    Convenient for NJ residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit New Brunswick site if eligible
  4. 4Begin participation

About This Grade 2 IDH1-mutant Glioma Study in New Brunswick

This study will include up to 40 participants with Grade 2 or Grade 3 IDH1-mutant glioma who have undergone surgery and received vorasidenib as their only treatment, experienced radiographic disease progression on vorasidenib (confirmed by Blinded Independent Central Review \[BICR\] per modified Response Assessment in Neuro-Oncology \[RANO\] 2.0), and are not in need of immediate chemotherapy or radiotherapy.

Sponsor: Nuvation Bio Inc.

Who Can Participate

Inclusion Criteria

Histologically confirmed Grade 2 or 3 IDH-mutant astrocytoma or IDH-mutant and 1p19q co-deleted oligodendroglioma, according to WHO CNS 2021 criteria
IDH1 mutation (e.g., R132H/C/G/S/L) based on immunohistochemistry (IHC) (R132H only), PCR, or next generation sequencing (NGS).
Have had at least 1 prior surgery for glioma (biopsy, sub-total resection, or gross total resection).
Measurable disease per modified RANO 2.0 confirmed by BICR during Screening.
Previously treated with vorasidenib and experienced radiographic disease progression during treatment and are not in need of immediate chemotherapy or radiotherapy in the opinion of the Investigator. Disease progression must be confirmed by BICR using modified RANO 2.0.
Adequate hematologic and organ function
Expected survival of ≥12 months Key

Exclusion Criteria

Any prior anticancer therapy other than surgery (biopsy, sub-total, or gross total resection) and vorasidenib for treatment of glioma.
Discontinued vorasidenib for toxicity or any reason other than radiographic disease progression
Prior treatment with anti-angiogenic agents such as Avastin (bevacizumab) or investigational agents for glioma.
Brainstem or spinal cord involvement either as primary location, site of multifocal involvement, or by significant tumor extension.
Significant functional or neurocognitive deficits, including uncontrolled seizures
Evidence of leptomeningeal disease.
Use of therapeutic doses of steroids for signs/symptoms of glioma. Participants taking physiologic doses (defined as equivalent of \<1.5 mg of dexamethasone equivalent) for medical conditions not related to glioma will be permitted.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in New Brunswick?

Yes, this clinical trial (NCT07703436) has an active research site in New Brunswick, NJ that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Grade 2 IDH1-mutant Glioma Treatment Options in New Brunswick, NJ

If you're searching for grade 2 idh1-mutant glioma treatment options in New Brunswick, NJ, this clinical trial (NCT07703436) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our New Brunswick research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced grade 2 idh1-mutant glioma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all grade 2 idh1-mutant glioma clinical trials near you to find additional studies recruiting in your area.

More Brain Cancer Trials in New Brunswick, NJ

See all brain cancer clinical trials recruiting in New Brunswick — not just this study.

Browse Brain Cancer Trials in New Brunswick →

Browse More Trials by Condition

Brain Cancer TrialsAlzheimers Disease TrialsRheumatoid Arthritis TrialsAtopic Dermatitis TrialsAll Conditions →

Ready to Join in New Brunswick?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · New Brunswick, NJ